Diagnostic delay in bronchiectasis: an Italian perspective.

It takes ∼3.5 years to reach a diagnosis of bronchiectasis from onset of symptoms: the long patient's journey in Italy https://bit.ly/46XMWAz.
Competing Interests: Conflict of interest: G. Sotgiu is an associate editor of this journal. Conflict of interest: A. Gramegna reports consulting fees from Vertex and Zambon, outside the submitted work; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Vertex, Chiesi and Insmed, outside the submitted work; support for attending meetings and/or travel from Neupharma, Chiesi and Insmed, outside the submitted work; participation on a Data Safety Monitoring Board or Advisory Board for Vertex, outside the submitted work. Conflict of interest: F. Blasi reports grants or contracts from AstraZeneca, Chiesi, GlaxoSmithKline and Insmed, outside the submitted work; consulting fees from GlaxoSmithKline, Menarini and OM Pharma, outside the submitted work; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca, Chiesi, GlaxoSmithKline, Grifols, Insmed, Menarini, Om Pharma, Pfizer, Sanofi, Vertex, Viatris and Zambon, outside the submitted work. Conflict of interest: C. Crimi reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, Sanofi, AstraZeneca, F&P, ResMed and Novartis, outside the submitted work; and patent pending number 102023000013077 not related to the submitted work. Conflict of interest: S. Aliberti reports grants or contracts from Insmed Incorporated, Chiesi, Fisher & Paykel and GSK, outside the submitted work; royalties or licenses from McGraw Hill, outside the submitted work; consulting fees from Insmed Incorporated, Insmed Italy, Insmed Ireland Ltd, Zambon Spa, AstraZeneca UK Limited, AstraZeneca Pharmaceutical LP, CSL Behring GmbH, Grifols, Fondazione Internazionale Menarini, Moderna, Chiesi, MSD Italia S.r.l., BRAHMS, Physioassist SAS and GlaxoSmithKline Spa, outside the submitted work; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from GlaxoSmithKline Spa, Thermofisher Scientific, Insmed Italy, Insmed Ireland Ltd, Zambon and Fondazione Internazionale Menarini, outside the submitted work; and participation on a Data Safety Monitoring Board or Advisory Board for Insmed Incorporated, Insmed Italy, AstraZeneca UK Limited and MSD Italia S.r.l, outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose.
(Copyright ©The authors 2024.)